Iraida Caballero Aguirrechu

Prof. Dr. Iraida Caballero Aguirrechu

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Frontiers in Pharmacology
Verified
Journal Article
Open access
IAIraida Caballero Aguirrechu
Iraida Caballero Aguirrechu
LALazaro E Aira
Lazaro E Aira
ALAnabel Lavastida
Anabel Lavastida
XPXitlally Popa
Xitlally Popa
JRJavier Rivero
Javier Rivero
ZMZaima Mazorra
Zaima Mazorra
Metastatic castration-resistant prostate cancer (CRPC) remains incurable due to the lack of effective therapies. Activation of the human epidermal growth factorreceptor 1 (HER1) in prostate cancer contributes to metastatic progression as well as to disease relapse. Here, we determined the toxicity and immunogenicity of a HER1-based cancer vaccine in CRPC patients included in a phase I clinical trial. CRPC patients (n=24) were intramuscularly vaccinated with HER1 vaccine consisting of the extracellular domain of HER1 molecule (ECD) and very small sizeproteoliposomefrom Neisseria meningitis(VSSP) and Montanide ISA-51 VG as adjuvants. Patients were included in five groups according to the vaccine dose (100 µg, 200 µg, 400 µg, 600 µg and 800 µg). The primary endpoints were safety and immunogenicity. The anti-HER1 antibodies were measured by an ELISA, the recognition of an HER1 positive tumor cell line and the inhibition of HER1 phosphorylation by sera were determined by flow cytometry and western blot analysis, respectively. The HER1-specific T cell response was assessed by determination of IFN--producing T cellsusing ELISpot assay. The vaccine was well tolerated. No grade III or IV adverse events were reported. High titers of anti-HER1 antibodies were observed in most of the evaluated patients. There were no significant differences regarding the geometric means of the anti-HER1 titers among the dose groupsexcept the group of 100 µg in which antidody titers were significantly lower.A Th1-type IgG subclasses pattern was predominant in most patients. Only patients receiving the higher doses of vaccine showed significant tumor cell recognition and HER1 phosphorylation inhibition by hyperimmune sera. Forty two percent of the patients showed a specific T cell response against HER1 peptides pool in post-treatment samples. There was a trend toward survival benefit in those patients showing high anti-HER1 specific antibody titers and a significant association between cellular immune response and clinical outcome.

1 August 2019 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
MCMarcela Cortés-Jofré
Marcela Cortés-Jofré
RURolando Uranga
Rolando Uranga
APAnia Torres Pombert
Ania Torres Pombert
MPMaria del Carmen Arango Prado
Maria del Carmen Arango Prado
IAIraida Caballero Aguirrechu
Iraida Caballero Aguirrechu
PBPedro Inocente Mas Bermejo
Pedro Inocente Mas Bermejo

15 June 2021 in Mexican Journal of Oncology
Verified
Journal Article
Closed access
DCDaniel Carballo-Torres
Daniel Carballo-Torres
IAIraida Caballero Aguirrechu
Iraida Caballero Aguirrechu
ISIrlis Sánchez-Rojas
Irlis Sánchez-Rojas
JGJavier González-Argote
Javier González-Argote
JOJorge Ortiz-Roque
Jorge Ortiz-Roque

10 June 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DPDaniel Pilco-Janeta
Daniel Pilco-Janeta
MPMyriam De la Cruz Puebla
Myriam De la Cruz Puebla
JSJorge Soriano
Jorge Soriano
MOMarta Osorio
Marta Osorio
IAIraida Caballero Aguirrechu
Iraida Caballero Aguirrechu
ACAdriana Carr
Adriana Carr
The aberrant expression of N-glycolyl GM3 ganglioside (NeuGcGM3) in patients with sarcomas was reevaluated by assessing the relation of this molecule with some clinicopathological features and overall survival (OS) of patients. Fifty formalin-fixed and paraffin-embedded specimens from patients diagnosed with sarcomas were included. For the evaluation of NeuGcGM3, the 14F7 monoclonal antibody followed by a peroxidase avidin-biotin system was used. Clinicopathological features were obtained from patient records. Survival rates were estimated by the Kaplan-Meier method and compared with the log-rank test. For multivariate analyses, the Cox regression model was used to identify independent prognostic factors for OS. The majority of samples had high levels of NeuGcGM3 expression (66.0%) that showed statistical correlation with age (p = 0.014), TNM stage (p = 0.022), histological grade (p = 0.013) and proliferation rates (p = 0.012). In addition, a tendency for association with tumor depth (p = 0.070) was evidenced. In univariate survival analysis, TNM stage (p = 0.000), occurrence of metastasis (p = 0.000) and expression of NeuGcGM3 (p = 0.034) were significant prognostic factors for OS, while a tendency for association was evidenced for histological grade (p = 0.091). Among these variables, only the presence of metastasis (p = 0.001) was an independent prognostic factor on multivariate analysis. The present research suggests the evaluation of NeuGcGM3 expression as a complementary prognostic factor in sarcoma, although our results need to be validated in a larger series and prospective studies. Moreover, our results could support the use of this molecule as a target for immunotherapy.

1 October 2012 in Virology
Verified
Journal Article
Closed access
VKVivian Kourí
Vivian Kourí
PMPedro A. Martínez
Pedro A. Martínez
VCVirginia Capó
Virginia Capó
OBOrestes Blanco
Orestes Blanco
MRMaría E Rodríguez
María E Rodríguez
UHUlrich Hengge
Ulrich Hengge

18 September 2020 in Ciencia y Salud
Verified
Journal Article
Open access
PDF file
MAMónica Carvajal Aballe
Mónica Carvajal Aballe
IAIraida Caballero Aguirrechu
Iraida Caballero Aguirrechu
El cáncer constituye un problema de salud mundial. Múltiples factores relacionados con la enfermedad y los tratamientos provocan predisposición a las infecciones en el paciente oncológico. La sepsis, constituye una importante causa de morbimortalidad. Se realizó un estudio descriptivo de corte transversal, con el objetivo de describir el comportamiento de las infecciones en pacientes con tumores sólidos en quimioterapia, atendidos en el servicio de Oncología Médica del Hospital Clínico Quirúrgico Hermanos Ameijeiras, de enero 2015 a enero 2017. La media de edad fue 53 años (32,3 %) y predominaron los pacientes masculinos (56.5 %). Los tumores de vías digestivas, carcinomas de pulmón y sarcomas de partes blandas representaron el 32.3, 25 y 13.7 %, respectivamente. De los 124 eventos de sepsis reportados, el 39.5 % fueron neutropenia febril, seguido por sepsis urinaria (34.7 %). En pacientes con otras infecciones, predominaron la nuemopatía inflamatoria y la mucositis grado IV. No existió asociación estadística significativa entre el esquema de quimioterapia y la aparición de infección. El avance y perfeccionamiento de los tratamientos han prolongado la vida de los pacientes y esto ha favorecido el mejor estudio y compresión de los diferentes eventos adversos, relacionados con la administración de quimioterapia.